Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) saw a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 339,948 shares, an increase of ∞ from the May 14th total of 0 shares. Based on an average daily trading volume, of 47,702,080 shares, the days-to-cover ratio is currently 0.0 days.
Regen BioPharma Stock Performance
Regen BioPharma has a fifty-two week low of $0.00 and a fifty-two week high of $0.12.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies.
Further Reading
- Five stocks we like better than Regen BioPharma
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
- Alphabet’s Most Overlooked Division Just Had a Big Week
- Cooking Up Profits: Cracker Barrel’s Turnaround
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
